Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 at JPMorgan Chase & Co.

Replimune Group (NASDAQ:REPL) had its target price increased by JPMorgan Chase & Co. from $16.00 to $18.00 in a report published on Wednesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other research firms have also weighed in on REPL. HC Wainwright raised their target price on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Jefferies Financial Group raised their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets raised their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Replimune Group presently has an average rating of “Buy” and a consensus price target of $19.43.

Replimune Group Trading Down 1.9 %

Shares of Replimune Group stock opened at $13.24 on Wednesday. The firm has a market capitalization of $1.02 billion, a PE ratio of -4.31 and a beta of 1.30. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00. The firm’s 50-day moving average price is $12.74 and its 200 day moving average price is $11.95. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last released its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). On average, sell-side analysts predict that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Several institutional investors have recently added to or reduced their stakes in the stock. Woodline Partners LP increased its holdings in Replimune Group by 156.6% in the 4th quarter. Woodline Partners LP now owns 854,309 shares of the company’s stock valued at $10,346,000 after purchasing an additional 521,366 shares during the last quarter. Velan Capital Investment Management LP acquired a new stake in Replimune Group in the 4th quarter valued at approximately $2,196,000. Soleus Capital Management L.P. acquired a new stake in Replimune Group in the 4th quarter valued at approximately $3,179,000. Two Sigma Investments LP increased its holdings in Replimune Group by 18.6% in the 4th quarter. Two Sigma Investments LP now owns 212,586 shares of the company’s stock valued at $2,574,000 after purchasing an additional 33,346 shares during the last quarter. Finally, Tang Capital Management LLC increased its holdings in Replimune Group by 125.0% in the 4th quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company’s stock valued at $32,697,000 after purchasing an additional 1,500,000 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.